4.7 Article

A prospective, multicenter cohort study to validate a simple performance status-based survival prediction system for oncologists

Journal

CANCER
Volume 123, Issue 8, Pages 1442-1452

Publisher

WILEY
DOI: 10.1002/cncr.30484

Keywords

Palliative Prognostic Index; prognostic score; prognostication; survival prediction; validation study

Categories

Funding

  1. National Cancer Center Research and Development Fund [25-A-22]

Ask authors/readers for more resources

BACKGROUNDSurvival prediction systems such as the Palliative Prognostic Index (PPI), which includes the Palliative Performance Scale (PPS), are used to estimate survival for terminally ill patients. Oncologists are, however, less familiar with the PPS in comparison with the Eastern Cooperative Oncology Group (ECOG) performance status (PS). This study was designed to validate a simple survival prediction system for oncologists, the Performance Status-Based Palliative Prognostic Index (PS-PPI), which is a modified form of the PPI based on the ECOG PS. METHODSThis multicenter, prospective cohort study enrolled all consecutive patients who were referred to 58 palliative care services in Japan. The primary responsible physicians rated the variables required to calculate the PS-PPI and the PPI. Patient survival in these risk groups was compared, and the sensitivity and specificity of the PS-PPI and the PPI were evaluated. Patients were subclassified as patients receiving care from in-hospital palliative care teams, palliative care units, or home-based palliative care services. Subsets of patients receiving chemotherapy were also analyzed. RESULTSThis study included 2346 patients. Survival predictions based on the PPI and the PS-PPI differed significantly among the 3 risk groups (P<.001). The PS-PPI was more sensitive, whereas the PPI was more specific. All areas under the receiver operating characteristic curves of both indices were >0.78 for predicting survival at all times, from 3 weeks to 180 days. CONCLUSIONSIn predicting the prognosis of patients with advanced cancer, the PS-PPI was as accurate as the PPI. The PS-PPI was useful for short- and long-term survival prediction and for the prediction of survival for patients undergoing chemotherapy. Cancer 2017;123:1442-1452. (c) 2016 American Cancer Society. The Performance Status-Based Palliative Prognostic Index, a simple system developed in this study, is a brief version of the Palliative Prognostic Index that uses the oncologist-familiar Eastern Cooperative Oncology Group performance status and that does not require specialist knowledge of palliative care. This multicenter, prospective cohort study of 2426 patients shows that the Performance Status-Based Palliative Prognostic Index predicts survival as accurately as the original Palliative Prognostic Index.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

The feasibility and effects of a pharmacological treatment algorithm for cancer patients with terminal dyspnea: A multicenter cohort study

Masanori Mori, Takashi Yamaguchi, Kozue Suzuki, Yoshinobu Matsuda, Ryo Matsunuma, Hiroaki Watanabe, Tomoo Ikari, Yoshihisa Matsumoto, Kengo Imai, Naosuke Yokomichi, Satoru Miwa, Toshihiro Yamauchi, Soichiro Okamoto, Satoshi Inoue, Akira Inoue, Tatsuya Morita, Eriko Satomi

Summary: This study examined adherence to a comprehensive pharmacological treatment algorithm for patients with terminal dyspnea and its outcomes. The results showed that the algorithm was feasible and effective in helping patients achieve treatment goals and reducing dyspnea levels significantly. Most adverse events were mild to moderate.

CANCER MEDICINE (2023)

Letter Geriatrics & Gerontology

Haloperidol-induced myoclonus in a patient with delirium

Tomomi Hayase, Hiroshi Saiga, Takashi Yamaguchi

GERIATRICS & GERONTOLOGY INTERNATIONAL (2023)

Article Health Care Sciences & Services

Should Benzodiazepines be Used for Reducing Dyspnea in Patients with Advanced Illnesses?

Steffen T. Simon, Masanori Mori, Magnus Ekstrom, Anne Pralong, Takashi Yamaguchi, David Hui

Summary: In summary, dyspnea is a common and distressing symptom in patients with advanced illnesses. Despite optimal management and non-pharmacologic interventions, many patients still experience chronic dyspnea, leading to the consideration of pharmacologic therapies. However, existing data suggests that benzodiazepines alone do not provide benefits for dyspnea in advanced illnesses. Concerns about potential adverse effects and recommendations against first-line use are also expressed. Selective use in patients with severe anxiety and adjunctive use in patients with severe dyspnea despite opioids may be considered. Further research is needed to confirm the efficacy of benzodiazepines in these populations.

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2023)

Article Health Care Sciences & Services

Systemic Opioids for Dyspnea in Cancer Patients: A Real-world Observational Study

Takashi Yamaguchi, Ryo Matsunuma, Yoshinobu Matsuda, Junichi Tasaki, Tomoo Ikari, Satoru Miwa, Sayo Aiki, Yusuke Takagi, Daisuke Kiuchi, Kozue Suzuki, Shunsuke Oyamada, Keisuke Ariyoshi, Kota Kihara, Masanori Mori

Summary: This study aims to evaluate the effectiveness and safety of systemic regular opioids for dyspnea in cancer patients in real-world palliative care practice. The results showed that regular systemic opioids were effective for relieving dyspnea in cancer patients and were well-tolerated.

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2023)

Review Oncology

Current Management Options for Dyspnea in Cancer Patients

Masanori Mori, Satoru Miwa, Tomoo Ikari, Jun Kako, Takaaki Hasegawa, Ryo Matsunuma, Kozue Suzuki, Yoshinobu Matsuda, Hiroaki Watanabe, Tatsuya Morita, Takashi Yamaguchi

Summary: Dyspnea is a common and distressing symptom in advanced cancer patients. Comprehensive assessment and timely treatment are important to improve quality of life. There is a lack of clinical trials on dyspnea in cancer patients, resulting in weak overall evidence. Recent studies on palliative care specialists' practice patterns provide valuable insights. This paper summarizes current management options, discusses controversies, and proposes future research directions for quality care.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2023)

Review Oncology

Opioids for the management of dyspnea in cancer patients: a systematic review and meta-analysis

Yusuke Takagi, Junya Sato, Yoshihiro Yamamoto, Ryo Matsunuma, Hiroaki Watanabe, Masanori Mori, Takaaki Hasegawa, Yoshinobu Matsuda, Jun Kako, Yoko Kasahara, Sho Goya, Hiroyuki Kohara, Takeo Nakayama, Takashi Yamaguchi

Summary: Dyspnea is a common symptom in cancer patients that significantly affects their quality of life. This study aimed to evaluate the efficacy and safety of opioids in treating dyspnea in cancer patients. The results showed that opioids were more effective than placebo in relieving dyspnea, but robust evidence is lacking.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Health Care Sciences & Services

Do Types of Opioids Matter for Terminal Cancer Dyspnea? A Preliminary Multicenter Cohort Study

Masanori Mori, Takashi Yamaguchi, Kozue Suzuki, Yoshinobu Matsuda, Ryo Matsunuma, Hiroaki Watanabe, Tomoo Ikari, Yoshihisa Matsumoto, Kengo Imai, Naosuke Yokomichi, Satoru Miwa, Toshihiro Yamauchi, Soichiro Okamoto, Satoshi Inoue, Akira Inoue, David Hui, Tatsuya Morita, Eriko Satomi, Japanese Dyspnea Relief Investigators

Summary: This study analyzed the effectiveness and safety of different medications for the treatment of dyspnea in cancer patients. The results showed that morphine, oxycodone, and hydromorphone were similarly effective in reducing dyspnea, with few adverse events.

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2023)

Article Health Care Sciences & Services

Should (Prophylactic) Medications Be Used for the Management of Death Rattle?

Harriette Johanna van Esch, Margret L. Campbell, Masanori Mori, Takayashi Yamaguchi

Summary: Death rattle is a common symptom in the dying phase and has different opinions regarding its management among experts. While explanation and reassurance may be sufficient, medication could be considered for relieving the symptom, especially considering the burden on relatives. The assessment and treatment of death rattle in the dying phase remains a matter of debate and further research is needed.

JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2023)

Article Health Care Sciences & Services

Validation of Modified Models of Objective Prognostic Score in Patients With Advanced Cancer

Seok-Joon Yoon, Sang-Yeon Suh, Yusuke Hiratsuka, Sung-Eun Choi, Sun-Hyun Kim, Su-Jin Koh, Shin Ae Park, Ji-Yeon Seo, Jung Hye Kwon, Jeanno Park, Youngmin Park, Sun Wook Hwang, Eon Sook Lee, Hong-Yup Ahn, Shao-Yi Cheng, Ping-Jen Chen, Takashi Yamaguchi, Satoru Tsuneto, Masanori Mori, Tatsuya Morita

Summary: This study aimed to validate modified models of objective prognostic score (OPS) with few or no laboratory tests for patients with advanced cancer. An observational study was performed on a cohort of patients in East Asia, and it was found that the modified OPS models had relatively good accuracy and calibration in predicting two-week survival.

JOURNAL OF PALLIATIVE MEDICINE (2023)

Article Health Care Sciences & Services

Clinicians' Prediction of Survival and Prognostic Confidence in Patients with Advanced Cancer in Three East Asian Countries

Eon Sook Lee, Yusuke Hiratsuka, Sang-Yeon Suh, Seon-Hye Won, Sun-Hyun Kim, Seok-Joon Yoon, Sung-Eun Choi, Hana Choi, Hong-Yup Ahn, Yoonjoo Kim, David Hui, Shao-Yi Cheng, Ping-Jen Chen, Chien-Yi Wu, Masanori Mori, Tatsuya Morita, Takashi Yamaguchi, Satoru Tsuneto

Summary: This study aimed to examine the accuracy and confidence of clinicians' prediction of survival in East-Asian countries. The results showed that clinicians had the highest accuracy in predicting 7-day survival, while the Performance Status-based Palliative Prognostic Index had lower accuracy.

JOURNAL OF PALLIATIVE MEDICINE (2023)

Article Health Care Sciences & Services

Continuous Deep Sedation for Psycho-Existential Suffering: A Multicenter Nationwide Study

Sayaka Maeda, Tatsuya Morita, Naosuke Yokomichi, Kengo Imai, Satoru Tsuneto, Isseki Maeda, Tomofumi Miura, Hiroto Ishiki, Hiroyuki Otani, Yutaka Hatano, Masanori Mori

Summary: This study investigated the use of continuous deep sedation (CDS) for psycho-existential suffering in patients. It found that patients without specific religious beliefs and those with a desire for hastened death may require CDS to alleviate their suffering. For these patients, CDS lasted longer and caused more discomfort for physicians, but it may lead to better therapeutic outcomes.

JOURNAL OF PALLIATIVE MEDICINE (2023)

Article Multidisciplinary Sciences

Comparison of survival times of advanced cancer patients with palliative care at home and in hospital

Jun Hamano, Ayano Takeuchi, Masanori Mori, Yasuhiro Saitou, Takahide Yamaguchi, Nobuyuki Miyata, Masakatsu Shimizu, Ryo Yamamoto, Yousuke Kimura, Yoshiyuki Kamiyama, Yasuyuki Arai, Hiroshi Matsuo, Hideki Shishido, Kazushi Nakano, Tomohiro Nishi, Hiroka Nagaoka, Naosuke Yokomichi, Isseki Maeda, Takashi Yamaguchi, Tatsuya Morita, Takuya Shinjo

Summary: This study aimed to compare the survival times of advanced cancer patients receiving home-based and hospital-based palliative care. After adjusting for symptoms and treatments, the study found that patients receiving home-based palliative care had significantly longer survival times than those receiving hospital-based care.

PLOS ONE (2023)

Editorial Material Health Care Sciences & Services

Malodour from oral malignant fungating wound: sprayed metronidazole - case report

Haruka Harano, Ryo Matsunuma, Yukako Tanaka-Yagi, Madoka Ito, Junichi Tasaki, Aki Egawa, Takashi Yamaguchi

Summary: Metronidazole gel or ointment is recommended for treating malodour in malignant fungating wounds, but may not work well in oral lesions due to discomfort and being washed out by saliva. Here we report a case where malodour caused by an oral lesion was effectively controlled with sprayed metronidazole.

BMJ SUPPORTIVE & PALLIATIVE CARE (2023)

Article Health Care Sciences & Services

Comparison of Symptom Severity and Progression in Advanced Cancer Patients Among Different Care Settings: A Secondary Analysis

Ryuto Shiraishi, Yoshiyuki Kizawa, Masanori Mori, Isseki Maeda, Yutaka Hatano, Hiroto Ishiki, Tomofumi Miura, Naosuke Yokomichi, Maiko Kodama, Keiko Inoue, Sen Otomo, Takashi Yamaguchi, Jun Hamano

Summary: This study compared the prevalence of symptom worsening between advanced cancer patients receiving palliative care at home and in palliative care units (PCUs). The results showed that patients receiving palliative care at home were more likely to experience worsening of pain and drowsiness. However, after adjusting for patient background, there was no significant difference in the prevalence of symptom worsening between patients receiving palliative care at home and in PCUs.

PALLIATIVE MEDICINE REPORTS (2023)

Article Oncology

Improved Symptom Change Enhances Quality of Dying in Patients With Advanced Cancer: An East Asian Cross-Cultural Study

Hsien-Liang Huang, Ping-Jen Chen, Masanori Mori, Sang-Yeon Suh, Chien-Yi Wu, Jen-Kuei Peng, Chih-Yuan Shih, Chien-An Yao, Jaw-Shiun Tsai, Tai-Yuan Chiu, Yusuke Hiratsuka, Sun-Hyun Kim, Tatsuya Morita, Takashi Yamaguchi, Satoru Tsuneto, David Hui, Shao-Yi Cheng

Summary: This study investigated how symptom changes affect the quality of dying and death for cancer patients. The results found that better symptom control, particularly for dyspnea and delirium, was associated with improved quality of dying and death.

ONCOLOGIST (2023)

No Data Available